Akamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload
Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to ...
A slow start for self-amplifying mRNA vaccines
A year after the first samRNA vaccine approval, experts say similar vaccines in development are likely to face scientific and ...
10 Best Depressed Stocks To Buy Heading into 2025
In one of our recent articles about 10 High Growth Non-Tech Stocks That Are Profitable in 2024, we talked about how the US ...
PharmTech16h
GSK, Cambridge to Partner on R&D for Kidney and Respiratory Diseases
The Cambridge-GSK Translational Immunology Collaboration builds on an existing scientific relationship between the biopharma company and the university, with the aim of improving outcomes for patients ...
De-extinction company provides a progress report on thylacine efforts
Colossal, the company founded to try to restore the mammoth to the Arctic tundra, has also decided to tackle a number of ...
RNA Interference Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Explore our latest breakthroughs in RNA Interference Research. Learn more about our innovative pipeline today! @ RNA ...
Allarity Therapeutics, Inc.: Allarity Therapeutics to be Granted European Patent for DRP Companion Diagnostic for Stenoparib
European Patent Office to grant a patent for DRP® companion diagnostic for Allarity's stenoparib cancer therapy Patent applications for the Stenoparib DRP® are also pending in the US, Japan, China, Au ...
New Discovery Preserves mRNA To Combat Cancer and Aging
The discovery of the first mRNA-stabilizing substance could pave the way for groundbreaking advancements in the development ...